The acquisition, pathologic analysis and molecular characterization of human and mouse model gastrointestinal (GI) samples is an integral requirement for all portions of this SPORE. This Core will continue to provide SPORE investigators multiple pathology services to support Research Projects and future Career Enhancement Program (CEP) and Developmental Projects (DP) awardees. We will work in close collaboration with investigators to achieve three crucial purposes: i) to provide tissue specimens and pathology expertise to evaluate human and mouse models of GI neoplasms; ii) to provide molecular pathologic expertise in state-of-the-art molecular evaluation of tissue specimens; and iii) to evaluate and implement new tissue and cellular imaging and analysis technologies that will benefit these research goals in the future. Centralization of Core activities builds upon established infrastructure and expertise of these investigators, and complements but does not replicate existing infrastructure in our Cancer Center and provides a valuable component to the analysis of biological resources developed and utilized by SPORE investigators. To bring pathology based scientific support to all SPORE projects, this Core proposes the following specific aims:
Specific Aim 1 : To provide human biospecimen procurement and distribution.
Specific Aim 2 : Generation of models for pre-clinical trials Specific Aim 3: Pathologic characterization of human and mouse GI tumors using molecular pathology tools and emerging new technologies

Public Health Relevance

The Biospecimen and Pathology Core will work in close collaboration with investigators to achieve three crucial purposes: i) to provide tissue specimens and pathology expertise to evaluate human and mouse models of GI neoplasms; ii) to provide molecular pathologic expertise in state-of-the-art molecular evaluation of tissue specimens; and iii) to evaluate and implement new tissue and cellular imaging and analysis technologies that will benefit these research goals in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127003-12
Application #
10005195
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2007-04-01
Project End
2024-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
12
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Babic, A; Schnure, N; Neupane, N P et al. (2018) Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 9:145
Lopes-Ramos, Camila M; Kuijjer, Marieke L; Ogino, Shuji et al. (2018) Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. Cancer Res 78:5538-5547
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230
Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822
Katona, Bryson W; Yurgelun, Matthew B; Garber, Judy E et al. (2018) A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med 20:1324-1327
Jeon, Jihyoun; Du, Mengmeng; Schoen, Robert E et al. (2018) Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology 154:2152-2164.e19
Kosumi, Keisuke; Hamada, Tsuyoshi; Koh, Hideo et al. (2018) The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol 188:2839-2852
Aguirre, Andrew J (2018) Refining Classification of Pancreatic Cancer Subtypes to Improve Clinical Care. Gastroenterology 155:1689-1691
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wang, Xiaoliang; Chan, Andrew T; Slattery, Martha L et al. (2018) Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk. Cancer Res 78:4790-4799

Showing the most recent 10 out of 590 publications